Biotie receives Orphan Drug Designation in the U.S.
The FDA has granted Orphan Drug Designation in the U.S. for Biotie's BTT1023 drug candidate for the treatment of primary sclerosing cholangitis (PSC). PSC is a chronic and progressive fibrotic liver disease for which there are currently no FDA-approved treatments. August 26, 2016